US court dismisses Takeda's claims against Hikma Pharmaceuticals
The US District Court for the district of Delaware has dismissed claims made by Takeda Pharmaceuticals USA against Hikma Pharmaceuticals and its wholly-owned US subsidiary West-Ward Pharmaceutical.
FTSE 250
20,522.81
16:38 14/11/24
n/a
n/a
FTSE 350
4,459.02
16:38 14/11/24
n/a
n/a
FTSE All-Share
4,417.25
16:54 14/11/24
n/a
n/a
Hikma Pharmaceuticals
1,794.00p
16:40 14/11/24
-0.83%
-15.00p
Pharmaceuticals & Biotechnology
19,794.96
16:38 14/11/24
0.96%
187.95
Takeda had alleged the infringement of patents covering methods of use of its colchicine product, Colcrys.
Since January 2015, Hikma has been marketing its own colchicine product under the brand name Mitigare, and selling an authorised generic, increasing patient access to the product in the US.
Chairman and chief executive Said Darwazah said: “This is a successful outcome and demonstrates our commitment to bringing more differentiated products to the US market."
At 1405 BST, Hikma shares were down 1.3% to 2,236p.